ライフサイエンスコーパス: deep venous thrombosis

1 y protocol to identify or exclude concurrent deep venous thrombosis.

2 ith malignancy after initiating treatment of deep venous thrombosis.

3 ous units, presence of fluid collection, and deep venous thrombosis.

4 nd a specificity of 100% for femoropopliteal deep venous thrombosis.

5 s) to determine the presence and location of deep venous thrombosis.

6 involvement, advanced immunosuppression, and deep venous thrombosis.

7 mbus, which was seen in 17% of patients with deep venous thrombosis.

8 etical cohorts of 60-year-old men with acute deep venous thrombosis.

9 reatment reduces mortality rates after acute deep venous thrombosis.

10 ight heparins may simplify the management of deep venous thrombosis.

11 t factor XIII Val34Leu is protective against deep venous thrombosis.

12 increased risk for venographically detected deep venous thrombosis.

13 antifibrin scintigraphy when used to detect deep venous thrombosis.

14 ular and femoral sites, and for diagnosis of deep venous thrombosis.

15 patients had supportive studies documenting deep venous thrombosis.

16 loodstream infections, and the prevalence of deep venous thrombosis.

17 after the computed tomography scan to detect deep venous thrombosis.

18 y embolisms, 11 (33.3%) were associated with deep venous thrombosis.

19 increase in the rate of lower limb proximal deep venous thrombosis.

20 venous access, lower extremity itching, and deep venous thrombosis.

21 patients having both pulmonary embolism and deep venous thrombosis.

22 ions, including bladder neck contracture and deep venous thrombosis.

23 ons, such as pulmonary embolism or recurrent deep venous thrombosis.

24 sis of pulmonary embolism or lower-extremity deep venous thrombosis.

25 drugs by the investigators; the patient had deep venous thrombosis.

26 t; in the placebo group, 1 patient developed deep venous thrombosis.

27 as 1.25 mm for pulmonary emboli and 5 mm for deep venous thrombosis.

28 provide recommendations to prevent in-flight deep venous thrombosis.

29 rs), stroke (9 more per 10 000 woman-years), deep venous thrombosis (12 more per 10 000 woman-years),

30 .9%) with ischemic stroke, and 1 (0.1%) with deep venous thrombosis; 28 patients (2.4%) died for card

31 Deep venous thrombosis (6%-32%) and inferior vena cava t

32 sed stroke (11 more per 10 000 woman-years), deep venous thrombosis (7 more per 10 000 woman-years),

33 sistent in patients with pulmonary embolism, deep venous thrombosis, a body weight >/=100 kg, moderat

34 Secondary outcomes included symptomatic deep venous thrombosis; all pulmonary embolisms; fatal p

35 h pulmonary embolism alone, 31 patients with deep venous thrombosis alone, and 58 patients with both.

36 Few studies have compared the incidence of deep venous thrombosis among ethnic groups.

37 gh well-established for suspected lower limb deep venous thrombosis, an algorithm combining a clinica

38 nt (0.8%) developed an asymptomatic proximal deep venous thrombosis and 7 patients (5.9%) developed d

39 ders have a very low incidence of idiopathic deep venous thrombosis and a very low relative risk for

40 sleep disturbance, head drop, prevention of deep venous thrombosis and end-of-life issues.

41 f 122 [2.5%]) and without (23 of 844 [2.7%]) deep venous thrombosis and in the age- and sex-matched U

42 patients, infections in 4 of 8 patients, and deep venous thrombosis and neutropenia in one patient ea

43 o receive oral contraceptives, there was one deep venous thrombosis and one clotted graft; in the pla

44 ong all 40 patients treated with MGDF, 1 had deep venous thrombosis and pulmonary embolism, and anoth

45 s to aid in the diagnosis of lower extremity deep venous thrombosis and pulmonary embolism.

46 o splenectomy; venous thromboembolism (VTE) (deep venous thrombosis and pulmonary embolus) after sple

47 ents developed thromboembolic complications (deep venous thrombosis and/or pulmonary emboli).

48 up, there were 1 death, 1 stroke, 2 cases of deep venous thrombosis, and 1 case of thrombosis in an a

49 ns due to medical care, respiratory failure, deep venous thrombosis, and sepsis.

50 transient neurologic ischemic attacks, four deep venous thrombosis, and two pulmonary emboli.

51 ldren and determining methods for diagnosing deep venous thrombosis associated with a catheter in the

52 It is critical to treat deep venous thrombosis at an early stage to avoid develo

53 or preventing mortality, pulmonary embolism, deep venous thrombosis, bleeding outcomes, or thrombocyt

54 , renal failure or insufficiency, pneumonia, deep venous thrombosis, bleeding, deep wound infection,

55 Risk for symptomatic deep venous thrombosis, but not risk for death or nonfat

56 Of the 176 patients, 35 (19.9%) had deep venous thrombosis by compression ultrasonography, i

57 heart failure, atrial fibrillation, stroke, deep venous thrombosis, cardiovascular death, and total

58 the first cycle of therapy due to toxicity (deep venous thrombosis, chest palpitations).

59 , history of cancer, past medical history of deep venous thrombosis, coma, and high platelet count.

60 Prophylaxis against deep venous thrombosis consisted of venous compression s

61 atheter use is complicated by a high risk of deep venous thrombosis despite antithrombotic prophylaxi

62 te risk reduction [ARR], 0.8%), asymptomatic deep venous thrombosis (DVT) (4 trials; relative risk [R

63 ed plasma fibrinogen is associated with both deep venous thrombosis (DVT) and its complication, pulmo

64 The mortality risks for patients with deep venous thrombosis (DVT) and pulmonary embolism (PE)

65 CS National Trauma Data Bank for episodes of deep venous thrombosis (DVT) and/or pulmonary embolism (

66 All of the available diagnostic tests for deep venous thrombosis (DVT) have limitations for exclud

67 ophilia therapy, but the risk of CVC-related deep venous thrombosis (DVT) in hemophiliacs is not well

68 The second was to confirm the absence of deep venous thrombosis (DVT) in patients with bilateral

69 asis pathways that have been associated with deep venous thrombosis (DVT) in the general population a

70 Deep venous thrombosis (DVT) is a common problem with po

71 effect of lipid lowering on the incidence of deep venous thrombosis (DVT) is controversial.

72 Deep venous thrombosis (DVT) is one of the most common c

73 However, it is associated with rates of deep venous thrombosis (DVT) of approximately 38% to 55%

74 tandard anticoagulation for acute, occlusive deep venous thrombosis (DVT) of the proximal lower extre

75 terature, the diagnostic role of d-dimer for deep venous thrombosis (DVT) or pulmonary embolism (PE)

76 t permits scintigraphic detection of chronic deep venous thrombosis (DVT) or pulmonary embolism (PE)

77 Deep venous thrombosis (DVT) remains a common and seriou

78 Clinical assessment of suspected deep venous thrombosis (DVT) should be based on systemat

79 The incidence of deep venous thrombosis (DVT) was 6.2% (n= 132), with sig

80 The presence of pulmonary embolism or deep venous thrombosis (DVT) was recorded for all patien

81 ctive evaluation of patients with cancer and deep venous thrombosis (DVT) who underwent FDG-PET and e

82 We also determined the association of deep venous thrombosis (DVT) with the presence of an IVC

83 ultrasonography cannot rule out symptomatic deep venous thrombosis (DVT) without further testing, su

84 urinary tract infection, pneumonia, sepsis, deep venous thrombosis (DVT), pulmonary embolism, venous

85 reated with any type of chemotherapy develop deep venous thrombosis (DVT).

86 ) is a common and burdensome complication of deep venous thrombosis (DVT).

87 is sensitive but not specific for diagnosing deep venous thrombosis (DVT).

88 aumatic PE might be different from those for deep venous thrombosis (DVT).

89 pool contrast agent, ferumoxytol, to depict deep venous thrombosis (DVT).

90 lant therapy from cancer patients with acute deep venous thrombosis (DVT; DVT + cancer group, n = 32)

91 ) disease, either pulmonary embolism (PE) or deep-venous thrombosis (DVT), at time of presentation; t

92 Standardised incidence ratios (SIR) of deep-venous thrombosis (DVT), pulmonary embolism, and ar

93 to four time after the original diagnosis of deep venous thrombosis; eight also underwent confirmator

94 dabigatran, anticoagulation in patients with deep venous thrombosis, estimation of warfarin dose, use

95 patients with PR3-ANCA, nine had documented deep venous thrombosis events, five of whom were positiv

96 This issue provides a clinical overview of deep venous thrombosis, focusing on prevention, diagnosi

97 al fibrillation (14 of 44 patients, 32%) and deep venous thrombosis (four of 44 patients, 9%).

98 These criteria may help distinguish acute deep venous thrombosis from the residual changes of prev

99 Grade 3 deep venous thrombosis, grade 3 back pain, and grade 3 v

100 ny as 50% of children with catheters develop deep venous thrombosis; however, most events are clinica

101 utpatients suspected of having first-episode deep venous thrombosis if results of simplified compress

102 is available about the prospective risk for deep venous thrombosis in specific high-risk clinical se

103 tation was not significantly associated with deep venous thrombosis in subgroups of patients receivin

104 vein compression accurately detects proximal deep venous thrombosis in symptomatic outpatients.

105 n is not a significant risk factor for acute deep venous thrombosis in this group of patients.

106 f 116 patients had pulmonary embolism and/or deep venous thrombosis, including 27 patients with pulmo

107 Deep venous valves are frequent sites of deep venous thrombosis initiation.

108 ining diagnostic imaging studies to rule out deep venous thrombosis is exacerbated by increased susce

109 for thrombolytic agents for less symptomatic deep venous thrombosis is undefined.

110 The causal relationship that deep venous thrombosis leads to impairment in lung funct

111 of CRT include pulmonary embolism, recurrent deep venous thrombosis, loss of central venous access, a

112 In a rat deep venous thrombosis model used to assess antithrombot

113 y bacterial or fungal infection (n = 7), and deep venous thrombosis (n = 1).

114 Other than deep venous thrombosis noted in some patients, no other

115 a, venous stenosis, right heart failure, and deep venous thrombosis occurred in 10, 7, 4, and 4 patie

116 nfidence interval 1.6-10) but not upper-limb deep venous thrombosis (odds ratio 0.6; 95% confidence i

117 ry embolism risk was increased by lower-limb deep venous thrombosis (odds ratio 4.0; 95% confidence i

118 ient died of fluid overload, and one died of deep venous thrombosis of calf veins with pulmonary thro

119 d graft; in the placebo group, there was one deep venous thrombosis, one ocular thrombosis, one super

120 Six patients presented with only a deep venous thrombosis or a pulmonary embolism; 1 patien

121 Documented VTE (deep venous thrombosis or pulmonary embolism) and unprov

122 ity, and 10 (20%) had thromboembolic events (deep venous thrombosis or pulmonary embolism).

123 Documented deep venous thrombosis or pulmonary embolism.

124 om 1982 to August 1994 for the occurrence of deep venous thrombosis or pulmonary embolism.

125 patients who have been given a diagnosis of deep venous thrombosis or pulmonary embolism.

126 est requiring cardiopulmonary resuscitation, deep venous thrombosis or thrombophlebitis, coma lasting

127 2.08 [95% CI, 1.41 to 3.06]); postoperative deep venous thrombosis (OR, 1.96 [95% CI, 1.18 to 3.26])

128 re the presence of hypercoagulability, prior deep venous thrombosis, or a cavopulmonary anastomosis.

129 venous line (P < .001), and prior PE and/or deep venous thrombosis (P < .001), were found to be sign

130 upper gastrointestinal bleeding, sepsis, or deep venous thrombosis (P=0.05).

131 ths of treatment, there was no recurrence of deep venous thrombosis, partial recanalization within af

132 on (APL), postoperative pulmonary embolus or deep venous thrombosis (PEDVT), foreign body left during

133 itors can prevent 4 instances of symptomatic deep venous thrombosis per 1000 treated patients (CI, 3

134 The annual incidence of idiopathic deep venous thrombosis per 1000000 persons older than 18

135 y analyses by varying in-hospital mortality, deep venous thrombosis prevalence, and ultrasound accura

136 Bedside consideration improved on the use of deep venous thrombosis prophylaxis (p < .05), stress ulc

137 Fifty-two patients (44%) were treated with deep venous thrombosis prophylaxis on postoperative day

138 embolic disease in pancreatic cancer include deep venous thrombosis, pulmonary embolism, disseminated

139 urinary tract infection, pneumonia, sepsis, deep venous thrombosis, pulmonary embolism, venous throm

140 001), other diseases of the vascular system (deep venous thrombosis/pulmonary embolism, peripheral va

141 sm has decreased over time, the incidence of deep venous thrombosis remains unchanged, indicating the

142 detecting underlying cancer in patients with deep venous thrombosis remains unknown.

143 for thromboembolic complications, including deep venous thrombosis, renal vein thrombosis, and pulmo

144 not increase the risk of lower limb proximal deep venous thrombosis (RR 0.97, 95% CI 0.72-1.29, P = 0

145 For idiopathic deep venous thrombosis, standardized age- and sex-adjust

146 (PTS), a substantial number of patients with deep venous thrombosis still develop PTS.

147 sible alternative outcome measure for future deep venous thrombosis studies.

148 Megestrol acetate had a higher rate of deep venous thrombosis than dexamethasone (5% v 1%; P =.

149 hildren are at increased risk for developing deep venous thrombosis, there are few pediatric studies

150 d heparin and mortality, pulmonary embolism, deep venous thrombosis, thrombocytopenia, and bleeding o

151 Among 89 patients with deep venous thrombosis, thrombosis was bilateral in 26,

152 Epidural catheters may directly prevent deep venous thrombosis through sympathetic blockade, res

153 duce thrombus burden in the setting of acute deep venous thrombosis to prevent both short- and long-t

154 been evaluated for suspected upper extremity deep venous thrombosis (UEDVT).

155 In patients with deep venous thrombosis, use of elastic compression stock

156 vs. 95.8 per 100,000), and the incidence of deep venous thrombosis was 3 times higher than that of p

157 The absolute incidence of deep venous thrombosis was 31% (95% CI, 15% to 47%) in p

158 The risk of deep venous thrombosis was assessed in the two randomize

159 Venographically diagnosed postoperative deep venous thrombosis was correlated with factor V geno

160 Deep venous thrombosis was diagnosed in 142 patients (14

161 Deep venous thrombosis was documented in 9 patients, and

162 at a median of 34 months after diagnosis of deep venous thrombosis was obtained through hospital cha

163 Deep venous thrombosis was seen in isolation in 14 patie

164 ad venous ultrasonography because idiopathic deep venous thrombosis was suspected.

165 patients with the first episode of proximal deep venous thrombosis were randomized to wear either th

166 that there was no difference in the risk of deep venous thrombosis when the femoral site was compare

167 as diagnosed in none of the 56 patients with deep venous thrombosis who did not have findings on the

168 We present the case of a man bedridden by deep venous thrombosis who was given intraclot instillat

169 ve lipomas, benign and malignant tumors, and deep venous thrombosis with pulmonary embolism.

170 There was one case of major deep venous thrombosis with pulmonary embolism.

171 h included 3.9% pulmonary embolism and 16.3% deep venous thrombosis, with 1.5% of patients having bot

172 small absolute risk reduction in symptomatic deep venous thrombosis without increasing bleeding.